Business Description
![Spero Therapeutics Inc Spero Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BCEW.png?12)
Spero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US84833T1034
Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 13.77 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.22 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.78 | |||||
Beneish M-Score | 22.69 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 433.9 | |||||
3-Year FCF Growth Rate | 45.5 | |||||
3-Year Book Growth Rate | -23.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28 | |||||
9-Day RSI | 29.21 | |||||
14-Day RSI | 34.09 | |||||
6-1 Month Momentum % | 66.67 | |||||
12-1 Month Momentum % | 2.94 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.53 | |||||
Quick Ratio | 3.53 | |||||
Cash Ratio | 2.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.9 | |||||
Shareholder Yield % | 1.23 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 27.69 | |||||
Net Margin % | 23.58 | |||||
FCF Margin % | -34.11 | |||||
ROE % | 32.02 | |||||
ROA % | 18.22 | |||||
ROIC % | 64.34 | |||||
ROC (Joel Greenblatt) % | 528.5 | |||||
ROCE % | 25.35 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 3.35 | |||||
PE Ratio without NRI | 2.82 | |||||
PS Ratio | 0.81 | |||||
PB Ratio | 0.71 | |||||
Price-to-Tangible-Book | 0.71 | |||||
EV-to-EBIT | 0.25 | |||||
EV-to-EBITDA | 0.24 | |||||
EV-to-Revenue | 0.06 | |||||
EV-to-Forward-Revenue | 0.13 | |||||
EV-to-FCF | -0.19 | |||||
Price-to-Graham-Number | 0.3 | |||||
Price-to-Net-Current-Asset-Value | 1.37 | |||||
Price-to-Net-Cash | 72 | |||||
Earnings Yield (Greenblatt) % | 400 | |||||
FCF Yield % | -42.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spero Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 96.735 | ||
EPS (TTM) ($) | 0.43 | ||
Beta | 0.07 | ||
Volatility % | 50.92 | ||
14-Day RSI | 34.09 | ||
14-Day ATR ($) | 0.09269 | ||
20-Day SMA ($) | 1.62725 | ||
12-1 Month Momentum % | 2.94 | ||
52-Week Range ($) | 0.99 - 1.995 | ||
Shares Outstanding (Mil) | 53.89 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Spero Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Spero Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Spero Therapeutics Inc Frequently Asked Questions
What is Spero Therapeutics Inc(SPRO)'s stock price today?
The current price of SPRO is $1.44. The 52 week high of SPRO is $2.00 and 52 week low is $0.99.
When is next earnings date of Spero Therapeutics Inc(SPRO)?
The next earnings date of Spero Therapeutics Inc(SPRO) is 2024-05-10 Est..
Does Spero Therapeutics Inc(SPRO) pay dividends? If so, how much?
Spero Therapeutics Inc(SPRO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |